Drug intelligence / Profile preview

xinmaitong pian

Development stage: Unknown
Lead developer: Guangdong Bangmin
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Xinmaitong Pian (心脉通片) is an approved traditional Chinese medicine (TCM) tablet developed and manufactured by Bangmin Pharmaceutical. It is formulated from a blend of ten Chinese herbs, including Radix Angelicae Sinensis (当归), Radix Salviae Miltiorrhizae (丹参), Radix Puerariae (葛根), and Radix Notoginseng (三七). Xinmaitong Pian is indicated for promoting blood circulation, removing blood stasis, dredging collaterals, nourishing the heart, and lowering blood pressure and blood lipids. It is clinically used in China for the treatment of hypertension and hyperlipidemia.

Other names: Xinmaitong PianXinmaitong tablets心脉通片

Beyond the preview

Go deeper on xinmaitong pian.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on xinmaitong pian.

Explore the full profile